Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAmortizatization of IntangiblesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Terns Pharmaceuticals (TERN) Change in Accured Expenses (2020 - 2025)

Terns Pharmaceuticals filings provide 6 years of Change in Accured Expenses readings, the most recent being $1.7 million for Q4 2025.

  • Quarterly Change in Accured Expenses fell 56.77% to $1.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $629000.0 through Dec 2025, down 85.18% year-over-year, with the annual reading at $629000.0 for FY2025, 85.18% down from the prior year.
  • Change in Accured Expenses hit $1.7 million in Q4 2025 for Terns Pharmaceuticals, down from $2.4 million in the prior quarter.
  • Across five years, Change in Accured Expenses topped out at $4.0 million in Q4 2024 and bottomed at -$5.3 million in Q1 2025.
  • Average Change in Accured Expenses over 5 years is $282550.0, with a median of $418500.0 recorded in 2022.
  • The largest annual shift saw Change in Accured Expenses crashed 700.0% in 2021 before it surged 4766.67% in 2022.
  • Terns Pharmaceuticals' Change in Accured Expenses stood at -$616000.0 in 2021, then skyrocketed by 319.16% to $1.3 million in 2022, then crashed by 42.81% to $772000.0 in 2023, then skyrocketed by 415.93% to $4.0 million in 2024, then crashed by 56.77% to $1.7 million in 2025.
  • Per Business Quant, the three most recent readings for TERN's Change in Accured Expenses are $1.7 million (Q4 2025), $2.4 million (Q3 2025), and $1.9 million (Q2 2025).